Neuralink wants to get a better look inside your head. Yes, I'm being literal. The Elon Musk-owned brain chip company is seeking to patent a method for an "automatic craniotomy" milling system - basically, a machine that precisely performs the surgery of opening the skull. Rather than a surgeon performing this surgery, this machine is operated by a controller that sets the "feed rate," or how fast the tool is going. This machine relies on data from two types of sensors: an impedance measurement system (which checks the patient's response to an electrical current) and an axial force sensor (which senses how much force the machine is using to cut through certain parts of the cranium). Coupled together, these measurements determine the feed rate in response to these measurements.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         Neuralink said that traditional craniotomy is often "a time-consuming and high risk proceedure, in part due to the reliance on manual cutting or drilling proceedures to create the surgical perforation of the cranium."  "Neurological implant devices are typically not size adjustable and must securely fit within the craniotomy location to prevent the intracranial structures remaining exposed after implantation," Neuralink noted. As such, there is little tolerance for human-caused inaccuracies in the craniotomy proceedure."  Last week, the company announced that it's been approved by the agency to conduct its first clinical trial on humans, which Neurolink called an "important first step that one day will allow our technology to help many people."